Abortion with sulprostone, a prostaglandin E2 derivative.
Sulprostone, a prostaglandin E2 derivative, was used in a multicenter trial to terminate 478 pregnancies of 8-21 weeks' gestation. The compound was clinically well accepted without premedication in extraovular, intravenous and intramuscular routes of administration. At 24 hours after treatment, 67%-88% of the patients had aborted, with a low average incidence of side effects. Sulprostone is preferred clinically to primary prostaglandins. Intravenous infusion was found to be the safest route, but intramuscular injection proved to be the most practical.
D000021:Abortifacient Agents, Steroidal / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral; D007273:Injections, Intramuscular; D011247:Pregnancy; D011458:Prostaglandins E / Q000008:administration & dosage* / Q000009:adverse effects
D000021:Abortifacient Agents, Steroidal; D011458:Prostaglandins E